• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Choong Ingrid

    9/5/23 9:38:59 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EIGR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Choong Ingrid

    (Last) (First) (Middle)
    C/O EIGER BIOPHARMACEUTICALS, INC.
    2155 PARK BLVD.

    (Street)
    PALO ALTO CA 94306

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Eiger BioPharmaceuticals, Inc. [ EIGR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Business Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/31/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $0.864 08/31/2023 A 54,000 (1) 08/30/2033 Common Stock 54,000 $0 54,000 D
    Explanation of Responses:
    1. The option vests in equal installments over 48 months measured from August 31, 2023, subject to the Reporting Person's continuous service as of each such date.
    /s/ James Vollins, Attorney-in-Fact for Ingrid C. Choong 09/05/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EIGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EIGR

    DatePrice TargetRatingAnalyst
    8/9/2021$26.00 → $27.00Buy
    Citigroup
    More analyst ratings

    $EIGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kayne Richard A bought $72,815 worth of shares (278,239 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:21:30 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kawas Leen bought $6,375 worth of shares (24,332 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:14:42 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Kayne Richard A claimed ownership of 5,096,986 shares (SEC Form 3)

    3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    10/30/23 4:53:52 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    SEC Filings

    View All

    SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.

    8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

    5/8/24 5:00:57 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Eiger BioPharmaceuticals Inc.

    8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

    5/2/24 4:32:02 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

    10-K/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

    4/29/24 4:33:07 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

    Announces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a "stalking horse" agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the "stalking horse" agreement, subject to court

    4/1/24 11:12:41 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

    Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone payment from AnGesZokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024)PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchin

    1/18/24 5:49:00 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

    PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requireme

    1/4/24 8:00:00 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kayne Richard A bought $72,815 worth of shares (278,239 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:21:30 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kawas Leen bought $6,375 worth of shares (24,332 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:14:42 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup reiterated coverage on Eiger BioPharmaceuticals with a new price target

    Citigroup reiterated coverage of Eiger BioPharmaceuticals with a rating of Buy and set a new price target of $27.00 from $26.00 previously

    8/9/21 8:38:42 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Financials

    Live finance-specific insights

    View All

    Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

    Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor

    6/29/23 8:00:00 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

    Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at

    6/28/23 4:05:00 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

    Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. The live and replayed webcast of the call will be available through the company's websi

    12/7/22 4:05:00 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Leadership Updates

    Live Leadership Updates

    View All

    Cutera Appoints Stephana Patton as Chief Legal Officer

    Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

    11/13/23 8:30:00 AM ET
    $CUTR
    $EIGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

    PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock. The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an

    5/3/23 4:05:00 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

    PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end.  D-LIVR is the largest trial conducted in HDV and if positive will support re

    1/6/22 8:00:00 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

    SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

    5/10/24 2:14:57 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

    SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

    2/14/24 4:03:08 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

    SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

    2/14/24 10:55:55 AM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care